Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer

NCT06349512 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT06349512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06349512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Recruiting
Start date
October 14, 2024
Completion date
November 30, 2032
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer